Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

The unexpected finding that the synthetic form of Vasoactive Intestinal Peptide (aviptadil) administered via inhalation was well tolerated and led to dampening of alveolar inflammation, radiological and clinical improvement of pneumonitis resulting from a checkpoint inhibitor therapy for melanoma, was the basis for this issued patent

~ posted by Jan, Y@h00 RLFTF finance conversations

Reply:

"The granting of this Swiss patent for the inhaled version of RLF-100 serves to further strengthen our growing intellectual property portfolio for this highly promising drug candidate" (RAM).

Our little peptide is still a promise and we won't drop it.

~ posted by Franz, Y@h00 RLFTF finance conversations